natgillin/translations-raw huggingface dataset:
In the tenofovir disoproxil fumarate treatment arm, 7% of patients discontinued treatment due to an adverse event; 9% of patients experienced a confirmed increase in serum creatinine of ≥ 0.5 mg/dl or confirmed serum phosphate of < 2 mg/dl through week 48; there were no statistically significant differences between the combined tenofovir-containing arms and the entecavir arm.
V skupini, ki je bila zdravljena z dizoproksiltenofovirijevim fumaratom, je do 48. tedna zdravljenja 7% bolnikov prekinilo zdravljenje zaradi neželenega učinka, 9% bolnikov je imelo potrjeno zvišanje serumske koncentracije kreatinina za ≥ 0,5 mg/dl ali potrjeno serumsko koncentracijo fosfata < 2 mg/dl; statistično značilnih razlik med kombiniranima skupinama, ki sta prejemali tenofovir, in skupino, ki je prejemala entekavir, ni bilo.
In the tenofovir disoproxil fumarate treatment arm, patients had a mean CPT score of 7.2, mean HBV DNA of
V skupini, ki je bila zdravljena z dizoproksiltenofovirijevim fumaratom, so imeli bolniki ob izhodiščni točki povprečno število točk po CPT lestvici 7,2, povprečno koncentracijo
In the third study dyspnoea was reported more frequently following Rapiscan (18% for patients with COPD; 11% for patients with asthma) than placebo, but at a lower rate than reported during clinical development (see Section 4.8).
V tretji študiji so o dispneji pogosteje poročali po dajanju zdravila Rapiscan (18% za bolnike s KOPB, 11% za bolnike z astmo) kot pri placebu, vendar pri nižji stopnji, kot je bila poročana med kliničnim razvojem (glejte poglavje 4.8).
In the third study in 1009 patients with mild or moderate asthma (n=537) and moderate or severe COPD (n=472) the incidence of FEV1 reduction >15% from baseline was 1.1% and 2.9% in patients with asthma (p=0.15) and 4.2% and 5.4% in patients with COPD (p=0.58) following Rapiscan and placebo dosing, respectively.
V tretji študiji pri 1009 bolnikih z blago do zmerno astmo (n=537) in zmerno do resno KOPB (n=472) je bila incidenca zmanjšanja FEV1 > 15% od izhodišča 1,1% in 2,9% pri bolnikih z astmo (p=0,15) in 4,2% in 5,4% pri bolnikih s KOPB (p=0,58) po dajanju zdravila Rapiscan in placeba.
In the third study in adults with hepatitis B and decompensated liver disease, 70% of patients taking Viread or entecavir had a viral level below 400 copies/ml.
V tretji študiji je bila pri 70 % bolnikov, ki so jemali zdravilo Viread ali entekavir, virusno breme pod 400 kopij/ml.
In the third study in women weighing 50 kg or more, 24 and 27% of women treated with Elonva and follitropin beta respectively became pregnant.
V tretji študiji pri ženskah s telesno maso nad 50 kg je zanosilo 24 % žensk, ki so se zdravile z zdravilom Elonva, in 27 % tistih, ki so se zdravile s folitropinom beta.
In the third study, 17 (61%) of the 28 patients responded to treatment with an improvement of at least one point on the disability scale.
V tretji študiji se je 17 (61 %) od 28 bolnikov odzvalo na zdravljenje z izboljšanjem za vsaj eno točko na lestvici prizadetosti.
In the third study, 334 patients received an injectable form of paliperidone for a mood episode for 6 months after which they either received placebo or continued treatment with injectable paliperidone.
V tretji študiji je 334 bolnikov šest mesecev prejemalo paliperidon v obliki injekcije za zdravljenje epizode razpoloženjske motnje, zatem pa so bodisi prejemali placebo bodisi nadaljevali zdravljenje s paliperidonom v obliki injekcije.
In the third study, 34% of patients (102 out of 298) with no advanced illness opened their bowels within four hours after the first injection, compared with 10% of those receiving placebo (16 out of 162).
V tretji študiji je 34 % (102 od 298) bolnikov brez napredovale bolezni blato odvedlo v štirih urah po prvem injiciranju zdravila v primerjavi z 10 % (16 od 162) tistih, ki so prejeli placebo.
In the third study, after 8 weeks of treatment patients who took Kalydeco had an average improvement of 10.7 percentage points more than those who took placebo.
Po osmih tednih zdravljenja se je predvidena vrednost FEV1 pri bolnikih, ki so jemali zdravilo Kalydeco, povprečno izboljšala za 10,7 odstotne točke več kot pri bolnikih, ki so jemali placebo.
In the third study, all 345 adults were taking ciclosporin, steroids and azathioprine (‘triple therapy’).
V tretji študiji je vseh 345 odraslih jemalo ciklosporin, steroide in azatioprin (trotirno zdravljenje).
In the third study, around 73% of previously untreated patients with wild-type RAS given Vectibix and FOLFIRI responded to treatment.
V tretji študiji se je na zdravljenje odzvalo okoli 73 % predhodno nezdravljenih bolnikov z divjim tipom gena RAS, ki so prejemali zdravilo Vectibix skupaj s kemoterapijo FOLFIRI.
In the third study, Gilenya was compared with beta- interferon over one year in 1,292 patients.
V tretji študiji so zdravilo Gilenya eno leto primerjali z beta-interferonom pri 1 292 bolnnikih.
In the third study, heart rhythm returned to normal in 47% of the patients receiving Brinavess compared with 14% of those receiving placebo.
V tretji študiji se je srčni utrip normaliziral pri 47 % prejemnikov zdravila Brinavess in pri 14 % prejemnikov placeba.
In the third study, involving 87 patients with field cancerisation (an area of sun damage with several actinic keratosis growths), Ameluz was compared with placebo used for one or two treatment sessions.
V tretji študiji s 87 bolniki so zdravilo Ameluz primerjali s placebom pri nanosu na celotno območje, ki so ga prizadele aktinične keratoze.
In the third study, patients who received Instanyl had faster pain relief than patients who received the comparator medicine.
V tretji študiji je prišlo pri bolnikih, ki so prejeli zdravilo Instanyl, do hitrejšega olajšanja bolečine kot pri bolnikih, ki so prejeli primerjalno zdravilo.
In the third study, platelet counts increased and were within normal levels in 83% of the patients, while 77% (10 out of 13 patients) with initially low platelet counts achieved platelet count normalisation.
V tretji študiji so se ravni trombocitov povečale in dosegle običajno raven pri 83 % bolnikov, medtem ko je pri 77 % (10 od 13) bolnikov z nizkimi začetnimi ravnmi trombocitov prišlo do normalizacije števila trombocitov.
In the third study, the number of relapses in patients receiving Gilenya was also around half the number seen in patients given beta-interferon.
V tretji študiji je bilo število recidivov pri bolnikih, ki so prejemali zdravilo Gilenya, prav tako približno za polovico manjše v primerjavi s številom recidivov pri bolnikih, ki so prejemali interferon beta.
In the third study, women taking Tyverb with trastuzumab lived without their disease getting worse for 12 weeks on average, compared with 8.1 weeks in those taking Tyverb alone.
V tretji študiji so bolnice, ki so prejemale zdravilo Tyverb v kombinaciji s trastuzumabom, v povprečju živele 12 tednov brez poslabšanja bolezni, medtem ko je to obdobje pri tistih, ki so prejemale le zdravilo Tyverb, znašalo 8,1 tedna.
In the three 12-week phase 3 double blind, placebo controlled studies, 88% of the patients completed treatment with Betmiga, and 4% of the patients discontinued due to adverse events.
V treh 12-tedenskih dvojno slepih, s placebom kontroliranih študijah 3. faze je 88 % bolnikov dokončalo zdravljenje z zdravilom Betmiga; 4 % bolnikov so zdravljenje prekinili zaradi neţelenih učinkov.
In the three 12-week phase 3 double blind, placebo controlled studies, treatment of the symptoms of OAB with mirabegron once daily resulted in a statistically significant improvement over placebo on the following health-related quality of life measures: treatment satisfaction and symptom bother.
V treh 12-tedenskih, dvojno slepih, s placebom kontroliranih študijah 3. faze je zdravljenje simptomov PASM z mirabegronom enkrat na dan v primerjavi s placebom statistično značilno izboljšalo zadovoljstvo z zdravljenjem in moteči vpliv simptomov (meri zdravstvene kakovosti ţivljenja).
In the three 6-month active-comparator-controlled studies, ANORO reduced the use of rescue medication with salbutamol compared with tiotropium, with statistically significant reductions observed in two of the studies (see Table 1).
V treh 6-mesečnih študijah kontroliranih z aktivno primerjalno učinkovino je zdravilo ANORO zmanjšalo uporabo rešilnega zdravila s salbutamolom v primerjavi s tiotropijem; v dveh od teh treh študij je bilo zmanjšanje statistično značilno (glejte preglednico 1).
In the three 6-month active-comparator-controlled studies, LAVENTAIR reduced the use of rescue medication with salbutamol compared with tiotropium, with statistically significant reductions observed in two of the studies (see Table 1).
V treh 6-mesečnih študijah kontroliranih z aktivno primerjalno učinkovino je zdravilo LAVENTAIR zmanjšalo uporabo rešilnega zdravila s salbutamolom v primerjavi s tiotropijem; v dveh od teh treh študij je bilo zmanjšanje statistično značilno (glejte preglednico 1).
In the three double-blind, placebo-controlled phase 3 studies in Dupuytren’s contracture, 73% of Xiapex-treated patients reported an ecchymosis or a contusion and 38% reported a haemorrhage at the injection site.
V treh dvojno slepih, s placebom nadzorovanih študijah faze 3 za Dupuytrenovo kontrakturo je 73 % bolnikov, ki so bili zdravljeni z zdravilom Xiapex, poročalo o pojavu ekhimoze ali kontuzije in 38 % o pojavu krvavitve na mestu injiciranja.
In the three largest clinical trials conducted in adult patients on dialysis, the median maintenance dose necessary to maintain the haematocrit between 30 to 36 % was approximately 75 IU/kg given 3 times per week.
V treh največjih kliničnih preskušanjih, izvedenih z odraslimi bolniki na dializi, je bil mediani vzdrževalni odmerek, potreben za ohranjanje hematokrita med 30 in 36 %, približno 75 i.e./kg trikrat na teden.
In the three minor surgeries that occurred during the study, Coagadex was rated as excellent in preventing bleeding episodes.
Pri treh manjših operacijah, ki so jih opravili med študijo, je bilo zdravilo Coagadex ocenjeno kot odlično za preprečevanje epizod krvavitev.
In the three smallest of these 20 subgroups, the point estimate of the hazard ratio exceeded 1.25; i.e., in subjects with no prior nephrectomy (n=186, HR=1.403, 95 % CI (0.955, 2.061)), baseline LDH > 1.5 x ULN (n=68, HR=1.72, 95 % CI (0.943, 3.139)), and MSKCC: poor risk (n=119, HR=1.472, 95 % CI (0.937, 2.313)).
V treh najmanjših od teh 20 podskupin je točkovna ocena razmerja ogroženosti presegla 1,25; te podskupine so bile preiskovanci brez predhodne nefrektomije (n = 186, Rog = 1,403, 95 % IZ (0,955, 2,061)), izhodiščna LDH > 1,5 x ZMN (n = 68, Rog = 1,72, 95 % IZ (0,943, 3,139)) in MSKCC: neugodno tveganje (n = 119, Rog = 1,472, 95 % IZ (0,937, 2,313)).
In the three studies in patients undergoing surgery, Xarelto was more effective than enoxaparin in preventing the formation of blood clots or death.
V treh študijah pri bolnikih po kirurškem posegu je bilo zdravilo Xarelto pri preprečevanju nastajanja krvnih strdkov ali smrti učinkovitejše od enoksaparina.
In the three studies of Exelon capsules in patients with Alzheimer’s dementia, patients taking doses of Exelon between 6 and 9 mg per day had an average increase in cognitive symptoms of 0.2 points from a baseline of 22.9 points at the start of the study, where a lower score indicates better performance.
V treh študijah zdravila Exelon pri bolnikih z Alzheimerjevo demenco je bilo pri tistih, ki so jemali od 6- do 9-miligramske odmerke zdravila Exelon, opaziti povprečno povečanje kognitivnih simptomov za 0,2 točke od izhodiščne vrednosti 22,9 točke na začetku študije, pri čemer nižji rezultat pomeni boljšo učinkovitost.
In the three studies of Rivastigmine 1 A Pharma in patients with Alzheimer’s dementia, patients taking doses of Rivastigmine 1 A Pharma between 6 and 9 mg per day had an average increase in cognitive symptoms of 0.2 points from a baseline of 22.9 points at the start of the study, where a lower score indicates better performance.
V treh študijah zdravila Rivastigmine 1 A Pharma pri bolnikih z Alzheimerjevo demenco je bilo pri tistih, ki so jemali od 6- do 9-miligramske odmerke zdravila Rivastigmine 1 A Pharma, opaziti povprečno povečanje kognitivnih simptomov za 0,2 točke od izhodiščne vrednosti 22,9 točke na začetku študije, pri čemer nižji rezultat pomeni boljšo učinkovitost.
In the three studies of Rivastigmine Hexal in patients with Alzheimer’s dementia, patients taking doses of Rivastigmine Hexal between 6 and 9 mg per day had an average increase in cognitive symptoms of 0.2 points from a baseline of 22.9 points at the start of the study, where a lower score indicates better performance.
V treh študijah zdravila Rivastigmine Hexal pri bolnikih z Alzheimerjevo demenco je bilo pri tistih, ki so jemali od 6- do 9-miligramske odmerke zdravila Rivastigmine Hexal, opaziti povprečno povečanje kognitivnih simptomov za 0,2 točke od izhodiščne vrednosti 22,9 točk na začetku študije, pri čemer nižji rezultat pomeni boljšo učinkovitost.
In the three studies of Rivastigmine Sandoz in patients with Alzheimer’s dementia, patients taking doses of Rivastigmine Sandoz between 6 and 9 mg per day had an average increase in cognitive symptoms of 0.2 points from a baseline of 22.9 points at the start of the study, where a lower score indicates better performance.
V treh študijah zdravila Rivastigmine Sandoz pri bolnikih z Alzheimerjevo demenco je bilo pri tistih, ki so jemali od 6- do 9-miligramske odmerke zdravila Rivastigmine Sandoz, opaziti povprečno povečanje kognitivnih simptomov za 0,2 točke od izhodiščne vrednosti 22,9 točk na začetku študije, pri čemer nižji rezultat pomeni boljšo učinkovitost.
In the Time to loss of virological response (TLOVR) analysis for the ITT(E) population, the proportion of patients achieving <400 copies/ml was 73 % (315 / 434) in the fosamprenavir with ritonavir group compared to 71 % (317 / 444) of patients receiving lopinavir / ritonavir, with a 95 % confidence interval of the difference of [-4,84%; 7;05%].
Analize časa do izgube virološkega odziva (TLOVR – »Time to loss of virological response«) pri vseh vključenih/izpostavljenih bolnikih (ITT(E) - »intent to treat«) kažejo, da je bila v skupini, ki je prejemala fosamprenavir skupaj z ritonavirjem, vrednost < 400 kopij/ml dosežena pri 73 % bolnikov (315/434), v skupini, ki je prejemala kombinacijo lopinavir/ritonavir, pa pri 71 % bolnikov (317/444); 95 % interval zaupanja [-4,84 %; 7,05 %].
In the Time to loss of virological response (TLOVR) analysis for the ITT(E) population, the proportion of patients achieving <400 copies/ml was 73 % (315 / 434) in the fosamprenavir with ritonavir group compared to 71 % (317 / 444) of patients receiving lopinavir / ritonavir, with a 95 % confidence interval of the difference of [-4,84%; 7;05%].
Analize časa do izgube virološkega odziva (TLOVR – »Time to loss of virological response«) pri vseh vključenih/izpostavljenih bolnikih (ITT(E) – »intent to treat«) kažejo, da je bila v skupini, ki je prejemala fosamprenavir skupaj z ritonavirjem, vrednost < 400 kopij/ml dosežena pri 73 % bolnikov (315/434), v skupini, ki je prejemala kombinacijo lopinavir/ritonavir, pa pri 71 % bolnikov (317/444); 95 % interval zaupanja [-4,84 %; 7,05 %].
In the Time to onset study, avanafil demonstrated statistically significant improvement in the primary efficacy variable (average per subject proportion of successful responses by time after dose administration, to the Sexual Encounter Profile 3 - SEP3) as compared with placebo, resulting in successful intercourse in 24.71% of the attempts for the 100 mg dose and 28.18% for the 200 mg dose at approximately 15 minutes after dosing compared to 13.78% for placebo .
V študiji “In the Time to onset” je avanafil izkazal statistično pomembno izboljšanje primarne spremenljivke za učinkovitost (povprečno število poskusov uspešnih spolnih odnosov (Sexual Encounter Profile 3 – SEP3) v času po odmerjanju) v primerjavi s placebom, kjer je bilo 24,71% uspešnih spolnih odnosov z odmerkom 100 mg in 28,18% z odmerkom 200 mg po pri približno 15 minutah po odmerku, medtem ko je s placebom izboljšanje 13,8%.
In the Time to onset study, avanafil demonstrated statistically significant improvement in the primary efficacy variable (average per subject proportion of successful responses by time after dose administration, to the Sexual Encounter Profile 3 – SEP3) as compared with placebo, resulting in successful intercourse in 24.71% of the attempts for the 100 mg dose and 28.18% for the 200 mg dose at approximately 15 minutes after dosing compared to 13.78% for placebo.
V študiji “In the Time to onset” je avanafil izkazal statistično pomembno izboljšanje primarne spremenljivke za učinkovitost (povprečno število poskusov uspešnih spolnih odnosov (Sexual Encounter Profile 3 – SEP3) v času po odmerjanju) v primerjavi s placebom, kjer je bilo 24,71% uspešnih spolnih odnosov z odmerkom 100 mg in 28,18% z odmerkom 200 mg po pri približno 15 minutah po odmerku, medtem ko je s placebom izboljšanje 13,8%.
In the TK007 clinical study only one 66-year-old female was treated with one infusion of Zalmoxis.
V klinični študiji TK007 je bila z eno infuzijo zdravila Zalmoxis zdravljena le ena 66-letna bolnica.
In the tocilizumab all exposure population, 11 patients (5.9%) experienced infusion reactions during the infusion and 38 patients (20.2%) experienced an event within 24 hours of an infusion.
V vsej populaciji, ki se je zdravila s tocilizumabom, je 11 bolnikov (5,9 %) imelo reakcijo, povezano z infundiranjem, med infundiranjem, 38 bolnikov (20,2 %) pa je imelo neželeni učinek v 24 urah po njem.
In the tocilizumab treated patients, 85% who had fever due to sJIA at baseline were free of fever (no temperature recording ≥ 37.5°C in the preceding 14 days) at week 12 versus 21% of placebo patients (p<0.0001).
Od bolnikov, ki so imeli pred začetkom zdravljenja povišano telesno temperaturo zaradi sJIA, jih 85 % v skupini, ki je prejemala tocilizumab, po 12 tednih ni imelo povišane telesne temperature (brez povišane telesne temperature ≥ 37,5°C v preteklih 14 dneh), v primerjavi z 21 % bolnikov, ki so prejemali placebo (p < 0,0001).
In the total population, there was a reduction in the incidence of laboratory-confirmed clinical influenza in households from 20 % (27/136) in the group not receiving prevention to 7 % (10/135) in the group receiving prevention (62.7 % reduction [95 % CI 26.0 – 81.2; p = 0.0042]).
V celotni populaciji je bilo zmanjšanje v pojavnosti klinične laboratorijsko potrjene influence v gospodinjstvu iz 20 % (27/136) v skupini, ki ni prejemala zdravila za preprečevanje, na 7 % (10/135) v skupini, ki je prejemala zdravilo za preprečevanje (62,7-% znižanje 95-% interval zaupanja 26,0–81,21; p = 0,0042).
In the toxicity studies, the plasma concentrations of lacosamide obtained were similar or only marginally higher than those observed in patients, which leaves low or non-existing margins to human exposure
V študijah toksičnosti so bile plazemske koncentracije lakozamida podobne ali le mejno povečane v primerjavi s koncentracijami, ki so jih opazili pri bolnikih, kar dovoljuje majhne ali neobstoječe mejne vrednosti izpostavljenosti pri človeku.
In the treated population, an increase in malformations has been noted with polytherapy; however, the extent to which the treatment and/or the illness is responsible has not been elucidated.
Pri zdravljeni populaciji so opazili zvečanje pogostnosti malformacij pri sočasnem zdravljenju z več različnimi zdravili; vendar ni jasno, koliko sta za to kriva zdravljenje in/ali bolezen.
In the treatment of acute STEMI, treatment should begin with a single rapid injection into your vein (intravenous injection), immediately followed by an injection underneath the skin (subcutaneous injection).
Pri akutnem STEMI je treba zdravljenje začeti z enkratno hitro injekcijo v veno (intravensko injiciranje), ki ji neposredno sledi injekcija pod kožo (subkutano injiciranje).
In the treatment of acute STEMI, treatment should begin with a single rapid injection into your vein (intravenous injection), immediately followed by an injection underneath the skin (subcutaneous injection).
Pri akutnem STEMI je treba zdravljenje začeti z enkratno hitro injekcijo v veno (intravensko injiciranje), ki ji takoj sledi injekcija pod kožo (subkutano injiciranje).
In the treatment of acute STEMI, treatment should begin with a single rapid intravenous injection, immediately followed by a subcutaneous injection.
Pri akutnem STEMI je treba zdravljenje začeti z enkratno hitro intravensko bolusno injekcijo, ki ji neposredno sledi subkutano injiciranje.
In the treatment of adults with chronic ITP, Revolade was more effective than placebo.
Pri zdravljenju kronične imunske trombocitopenične purpure je bilo zdravilo Revolade učinkovitejše od placeba.
In the treatment of AML, it is thought to work by protecting immune system cells from damage.
Predvideva se, da pri zdravljenju akutne mieloidne levkemije ščiti celice imunskega sistema pred poškodbami.
In the treatment of BRD ZACTRAN was shown to be as effective as tulathromycin.
Pri zdravljenju respiratorne bolezni govedi se je zdravilo ZACTRAN izkazalo za enako učinkovito kot tulatromicin.
In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased.
Pri zdravljenju centralne nevropatske bolečine kot posledice poškodbe hrbtenjače je bila zvečana incidenca neželenih učinkov na splošno, neželenih učinkov, povezanih z osrednjim živčnim sistemom, in še posebno somnolence.
In the treatment of Crohn’s disease, Stelara (concentrate for infusion) was compared with placebo in two main studies involving 1,369 patients with moderately to severely active disease.
Pri zdravljenju Crohnove bolezni so zdravilo Stelara (koncentrat za infundiranje) primerjali s placebom v dveh glavnih študijah, v kateri je bilo vključenih 1 369 bolnikov z zmerno do hudo aktivno boleznijo.
In the treatment of flu in full-term babies up to 1 year of age, this medicine should be given a liquid form to be taken by mouth (oral suspension) in a dose of 3 mg per kg body weight twice a day.
Pri zdravljenju gripe pri pravočasno rojenih novorojenčkih, starih do enega leta, se zdravilo daje peroralno v tekoči obliki (peroralna suspenzija) dvakrat na dan v odmerku 3 mg na kg telesne mase.
in the treatment of flu, it can be used in adults and children (including full-term newborns) who have the symptoms of flu, when the flu virus is known to be circulating in the community; in the prevention of flu, it can be used in adults and children over 1 year of age who have been in contact with someone who has flu.
pri zdravljenju gripe se lahko uporablja pri odraslih in otrocih (vključno s pravočasno rojenimi novorojenčki), ki imajo simptome gripe, kadar je virus gripe prisoten v okolici; pri preprečevanju gripe se lahko uporablja pri odraslih in otrocih, starejših od enega leta, ki so bili v stiku z osebo, okuženo z gripo.
in the treatment of flu, it can be used in adults and children (including full-term newborns) who have the symptoms of flu, when the flu virus is known to be circulating in the community; in the prevention of flu, it can be used in adults and children over one year of age who have been in contact with someone who has flu.
pri zdravljenju gripe se lahko uporablja pri odraslih in otrocih (vključno z donošenimi novorojenčki), ki imajo simptome gripe, kadar je virus gripe prisoten v okolici; pri preprečevanju gripe se lahko uporablja pri odraslih in otrocih, starejših od enega leta, ki so bili v stiku z osebo, okuženo z gripo.
In the treatment of genital warts, the total clearance rate across the four main studies was 15 to 52% in the Aldara-treated patients, compared with 3 to 18% in the placebo-treated patients.
Pri zdravljenju bradavic na spolovilu je stopnja popolne odstranitve v štirih glavnih študijah znašala 15 do 52 % pri bolnikih, ki so se zdravili z zdravilom Aldara, v primerjavi s 3 do 18 % pri bolnikih, ki so se zdravili s placebom.
In the treatment of myelodysplastic syndromes, the recommended dose of Revlimid is 10 mg a day.
Pri zdravljenju mielodisplastičnih sindromov je priporočeni odmerek zdravila Revlimid 10 mg na dan.